Table 2.
Peripheral blood leukocyte populations in healthy subjects and arthritic patients.
| Leukocyte population (cells/mm3) | Healthy subjects | Arthritic patients | ||
|---|---|---|---|---|
| NST | LFN | ADA | ||
| CD4+ | 309.9 ± 192.6 | 420.0 ± 326.2 | 186.5 ± 90.7# | 501.0 ± 349.2 |
| CD4+CD25+CD127high | 32.7 (21.3–51.8) | 42.0 (27.5–132.6) | 19.8 (13.2–24.3)# | 47.8 (16.7–100.5) |
| CD4+CD25+CD127low | 33.6 ± 16.1 | 43.3 ± 30.5 | 19.5 ± 11.7# | 51.2 ± 35.1 |
| CD4+CD69+ | 51.3 ± 33.0 | 93.8 ± 104.7 | 36.7 ± 24.6 | 75.8 ± 58.5 |
| CD8+ | 138.6 ± 63.3 | 254.9 ± 276.8 | 108.6 ± 73.3# | 272.0 ± 237.4 |
| CD8+CD69+ | 23.0 ± 16.8 | 38.9 ± 33.8 | 17.1 ± 16.1 | 44.0 ± 47.3 |
| CD19+ | 33.6 (20.4–45.5) | 60.2 (17.0–101.1) | 38.3 (19.8–75.7) | 103.4 (22.9–148.7) |
| CD19+CD69+ | 8.5 ± 5.4 | 28.2 ± 34.8 | 17.5 ± 14.2 | 17.5 ± 19.2 |
Samples were obtained from patients with rheumatoid arthritis (RA) treated or not with either leflunomide (LFN; n = 15) or adalimumab (ADA; n = 15) and compared with patients recently diagnosed with RA but not yet receiving specific treatment with anti-rheumatic drugs (NST group; n = 10) and healthy subjects (n = 15). Data are expressed as mean ± SD. #p < 0.05, differs from the NST group. Variables are expressed as mean ± SD or median (25–75th percentile; IQR).